- Home
- ELDN vs SCPH Comparison
ELDN vs SCPH Comparison
Compare ELDN & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- SCPH
- Stock Information
- Founded
- ELDN 2004
- SCPH 2013
- Country
- ELDN United States
- SCPH United States
- Employees
- ELDN N/A
- SCPH N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- ELDN Health Care
- SCPH Health Care
- Exchange
- ELDN Nasdaq
- SCPH Nasdaq
- Market Cap
- ELDN 202.4M
- SCPH 173.6M
- IPO Year
- ELDN N/A
- SCPH 2017
- Fundamental
- Price
- ELDN $2.59
- SCPH $5.58
- Analyst Decision
- ELDN Strong Buy
- SCPH Buy
- Analyst Count
- ELDN 2
- SCPH 3
- Target Price
- ELDN $12.50
- SCPH $12.00
- AVG Volume (30 Days)
- ELDN 683.9K
- SCPH 2.3M
- Earning Date
- ELDN 08-14-2025
- SCPH 08-07-2025
- Dividend Yield
- ELDN N/A
- SCPH N/A
- EPS Growth
- ELDN N/A
- SCPH N/A
- EPS
- ELDN 0.21
- SCPH N/A
- Revenue
- ELDN N/A
- SCPH $49,969,000.00
- Revenue This Year
- ELDN N/A
- SCPH $108.95
- Revenue Next Year
- ELDN N/A
- SCPH $78.30
- P/E Ratio
- ELDN $12.78
- SCPH N/A
- Revenue Growth
- ELDN N/A
- SCPH 107.79
- 52 Week Low
- ELDN $2.38
- SCPH $1.94
- 52 Week High
- ELDN $5.54
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- ELDN 41.11
- SCPH 63.23
- Support Level
- ELDN $2.54
- SCPH $4.33
- Resistance Level
- ELDN $2.84
- SCPH $5.62
- Average True Range (ATR)
- ELDN 0.13
- SCPH 0.13
- MACD
- ELDN 0.03
- SCPH 0.04
- Stochastic Oscillator
- ELDN 22.73
- SCPH 96.51
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.